Resistance to antimicrobial drugs threatens our ability to treat infectious diseases, increases health costs, and poses a serious risk to the progress made in global health in the past decades.

The increase in the number of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) and the emergence of carbapenemases-producing Enterobacteriaceae (CPE) has become a worrisome clinical issue.